T1	Participants 501 723	452 patients considered valid for clinical efficacy, faropenem daloxate treatment was found to be statistically equivalent to cefuroxime axetil (89.0% vs. 88.4%-95% CI=-5.2%; +6.4%) at the 7-16 days post-therapy assessment
T2	Participants 914 988	148 organisms was obtained in 136 microbiologically valid patients (30.1%)
